Development and validation of blood-based predictive biomarkers for response to PD-(L)-1 checkpoint inhibitors: evidence of a universal systemic core of 3D immunogenetic profiling across multiple oncological indications.
Hunter, E.; Dizfouli, M.; Koutsothanasi, C.; Wilson, A.; Santos, F. C.; Salter, M.; Westra, J.; Powell, R.; Dring, A.; Egan, B.; Parnall, M.; Thacker, M.; Green, J.; Ramadass, A.; Ng, S.; Lim, C. R.; Keat, C. S.; Suan, A. T.; Raman, R.; Fatt, H. K.; Wei Luen, F. L.; Heaton, R.; Levine, J.; Akoulitchev, A.
Show abstract
Unprecedented advantages in cancer treatment with immune checkpoint inhibitors (ICI) remain limited to a subset of patients. Systemic analyses of the regulatory 3D genome architecture linked to individual epigenetics and immunogenetic controls associated with tumour immune evasion mechanisms and immune checkpoint pathways reveals a highly prevalent patient molecular profiles predictive of response to PD-(L)1 immune checkpoint inhibitors. A clinical blood test based on the set of 8 3D genomic biomarkers has been developed and validated on several independent cancer patient cohorts to predict response to PD-(L)1 immune checkpoint inhibition. The predictive 8 biomarker set is derived from prospective observational clinical trials, representing 229 treatments with Pembrolizumab, Atezolizumab, Durvalumab, in diverse indications: melanoma, non-small cell lung, urethral, hepatocellular, bladder, prostate cancer, head and neck, vulvar, colon, breast, bone, brain, lymphoma, larynx cancer, and cervix cancers. The 3D genomic 8 biomarker panel for response to immune checkpoint therapy achieved high accuracy up to 85%, sensitivity of 93% and specificity of 82%. This study demonstrates that a 3D genomic approach could be used to develop a predictive clinical assay for response to PD-(L)1 checkpoint inhibition in cancer patients.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- From Mutation to Prognosis: AI-HOPE-PI3K Enables Artificial Intelligence-Agent Driven Integration of PI3K Pathway Data in Colorectal Cancer Precision Medicine 93%
- Unveiling epigenetic regulatory elements associated with breast cancer development 92%
- Immunohistochemical Profiling of Histone Modification Biomarkers Identifies Subtype-Specific Epigenetic Signatures and Potential Drug Targets in Breast Cancer 91%
Similar papers in this journal
- Spatial tumour gene signature discriminates neoplastic from non-neoplastic compartments in colon cancer: unravelling predictive biomarkers for relapse 93%
- Genomic Insights Guiding Personalized First-Line Immunotherapy Response in Lung and Bladder Tumors 92%
- A modular framework for the development of targeted Covid-19 blood transcript profiling panels 90%
Similar papers in this journal
- Utilisation of semiconductor sequencing for the detection of predictive biomarkers in glioblastoma 94%
- Shedding Light on the Dark Genome: Insights into the Genetic, CRISPR-based, and Pharmacological Dependencies of Human Cancers and Disease Aggressiveness 93%
- Combining explainable machine learning, demographic and multi-omic data to identify precision medicine strategies for inflammatory bowel disease 92%
Similar papers in this journal
- Use of high-plex data reveals novel insights into the tumour microenvironment of clear cell renal cell carcinoma 94%
- Protein profiling of breast carcinomas reveals expression of immune-suppressive factors and signatures relevant to patient outcome 93%
- Genomic profile in TGCT Mexican patients reveals a potential biomarker of sensitivity to platinum-based therapy 92%
Similar papers in this journal
- Added-value of whole exome and RNA Sequencing in advanced and refractory cancer patients with no molecular-based treatment recommendation based on a 90-gene panel 93%
- Combination of hotspot mutations with methylation and fragmentomic profiles to enhance Multi-Cancer Early Detection 92%
- Restriction site associated DNA sequencing for tumour mutation burden estimation and mutation signature analysis 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.